

For Immediate Release

Contact: Neal Koller  
President & CEO  
+1 (610) 539-3670

**PluroGen Therapeutics, Inc. Announces**

**US Patent Claims Allowed**

**For PluroGen's Nano-silver Antimicrobial Technology**

Norristown, Pennsylvania, 30 July 2014

PluroGen Therapeutics, Inc., leading solutions for wound, burn and skin care with its advanced PluroGel® Biomaterial surfactant products, announced today that it received notice from the United States Patent and Trademark Office (USPTO) that new patent claims will be allowed for its Nano-silver antimicrobial technology. PluroGen expects a new patent to issue.

The claims noted by the USPTO that will be allowed cover what the Company anticipates is a next generation antimicrobial technology to be used for products based on PluroGen's patented Polysaccharide Natural Gel Technology and its patented advanced PluroGel® Biomaterial. Silver has long been used as an antimicrobial material. The advantage of Nano-silver is the silver particles are much smaller than typical silver products which provides much more silver surface area. This increased silver surface area is thought to have the benefit of more effective antimicrobial activity and the possibility of reduction of the amount of silver needed in a product.

"A new patent that will provide protection for a next generation antimicrobial technology will be an important new asset and addition to the Company's intellectual property portfolio" commented Neal Koller, President and CEO of PluroGen.

**About PluroGen Therapeutics**

PluroGen Therapeutics, Inc. is a biotechnology company that provides clinically advanced topical anti-infective products for diabetic ulcers, chronic (nonhealing) wounds and burns. The company developed its core family of PluroGel® products by utilizing its patent-protected advanced PluroGel® Biomaterial. In working closely with doctors, nurses, patients and healthcare institutions, PluroGel® products have been routinely used with documented superior results on more than 14,000 patients in and outside of the USA. More information can be found on the company web site at [www.plurogen.com](http://www.plurogen.com). For PluroGen Investor Information please call +1 (610) 539-3670.

**Safe Harbor Statement:**

The statements in the press release that relate to PluroGen's (the company) expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.